SPHS $1.08 + $.20 has room to run Prostate cancer is treatable with surgery but unfortunately leaves many side effects because the treatment targets the entire prostate, and can cause incontinence and impotence.
SPHS has a HUGE potential market because it targets ONLY the cancerous area within the prostate, avoiding the side effects.
IMO a $50 million market cap ($3.50 per share) is still DIRT CHEAP for the potential market for this stock.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.